Promising results for new oral microbiome drug for C. diff

In PRISM3, a multicenter, randomized, double-blind, placebo-controlled phase 2 trial, researchers assessed an investigational oral microbiome drug CP101 in 206 patients with recurrent C. difficle at 51 sites across the United States and Canada. The drug did meet the primary endpoint of sustained clinical cure among 74.5% of the patients with recurrent C. difficile who received a

Common Food Additive May promote C. diff

An article appearing in Nature suggested that a common food additive known as trehalose might be responsible for the current Clostridium difficile epidemic. The Nature paper shows us that two of the most virulent strains of C. diff, including the “hypervirulent” ribotype 027, can metabolize even trace amounts of trehalose. They go on to show that when strains are mixed together, low